WooGene B&Gco우진비앤지
018620 · KOSDAQ · ₩018620 · 우진비앤지
- Market cap
- ₩19B
- Enterprise value
- ₩35B
- P/E
- —
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- −7.8%
- Net margin
- −4.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.7% from the high
₩2,120Today: ₩2,715 – ₩2,900₩4,363
Returns
- 1W−3.8%
- 1M+1.8%
- 3M+6.0%
- 6M−11.3%
- YTD−20.4%
- 1Y−23.0%
- Volume today
- 17,356
- 1.0× the 20-day average
- Traded today
- ₩48M
- Listed shares
- 6,932,982
- EPS (12 months)
- −₩360
- Earnings yield −13.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat2.2% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
WooGene B&Gco stock overview
WooGene B&Gco (우진비앤지, KRX: 018620) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean animal medicine specialist that develops, manufactures and supplies veterinary drugs, including antibiotics, nutritional supplements, disinfectants, microbial products, feed supplements and vaccines, with some human-use pharmaceutical ingredients. Its shares closed at ₩2,760 on Oct 30, 2026, down 4.33% on the day, giving it a market value of ₩19B.
Key facts
- Market cap
- ₩19B
- Sector
- Biotech & Pharma
- Latest price change
- −4.33%
- As of
- Oct 30, 2026
- Main business
- The company is a Korean animal medicine specialist that develops, manufactures and supplies veterinary drugs, including antibiotics, nutritional supplements, disinfectants, microbial products, feed supplements and vaccines, with some human-use pharmaceutical ingredients.
Quick answers about WooGene B&Gco
- What does WooGene B&Gco do?
- The company is a Korean animal medicine specialist that develops, manufactures and supplies veterinary drugs, including antibiotics, nutritional supplements, disinfectants, microbial products, feed supplements and vaccines, with some human-use pharmaceutical ingredients. It sells through distributors, directly to companies, and to government offices nationwide via the Public Procurement Service, and exports roughly 39% of its sales. Its subsidiaries make pet food and pet treats: OSP focuses on ODM dry pet food for dogs and cats under its own INDIGO brands, and Bowwow Korea produces and sells wet and dry pet food and treats in Korea and overseas markets including the US, Hong Kong and Southeast Asia.
- What is the market cap of WooGene B&Gco?
- The market capitalisation of WooGene B&Gco was ₩19B at the close on Oct 30, 2026.
- Who are the largest shareholders of WooGene B&Gco?
- According to the latest official filings, the largest reported holders are Kang Jae-gu (31.50%, as of Sep 30, 2026); Kang Seok-jin (7.33%, as of Jun 9, 2026); Im Jae-chun (0.05%, as of Jun 22, 2026).
- When is the next earnings report from WooGene B&Gco?
- Korean companies rarely announce results dates in advance. Based on when WooGene B&Gco filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean animal medicine specialist that develops, manufactures and supplies veterinary drugs, including antibiotics, nutritional supplements, disinfectants, microbial products, feed supplements and vaccines, with some human-use pharmaceutical ingredients. It sells through distributors, directly to companies, and to government offices nationwide via the Public Procurement Service, and exports roughly 39% of its sales. Its subsidiaries make pet food and pet treats: OSP focuses on ODM dry pet food for dogs and cats under its own INDIGO brands, and Bowwow Korea produces and sells wet and dry pet food and treats in Korea and overseas markets including the US, Hong Kong and Southeast Asia.
Written by AI from the company's latest annual report.
- Korean name
- 우진비앤지
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 강재구
- Founded
- Dec 1985
- Listed
- May 2008
- Listed shares
- 6,932,982
- Fiscal year ends
- Month 12
- Website
- www.woogenebng.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Insider shareholding reportSep 30, 2026
- 5%+ holding reportSep 30, 2026
- Insider shareholding reportAug 25, 2026
- 5%+ holding reportAug 25, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: WooGene B&Gco / 우진비앤지 / 018620 / KRX:018620
Source: KRX statistical information